Introduction: Lenvatinib mesylate is the mesylate of lenvatinib, a multi-target tyrosine kinase inhibitor developed by Eisai, Japan, which has a novel combination of In addition to inhibiting other pro-angiogenic and oncogenic signaling pathway-related tyrosine kinases involved in tumor proliferation, it can also selectively inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2 and VEGF-3, etc.
Structural formula:
Properties
Summary
Lovatinib mesylate is the mesylate of lovatinib. Lovatinib is a multi-target tyrosine kinase inhibitor developed by Japan Weicai company. It has a novel binding mode. In addition to inhibiting other tyrosine kinases related to angiogenesis and carcinogenic signal pathways involved in tumor proliferation, It can also selectively inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptor, such as VEGF-1, VEGF-2 and vegf-3.
CRO
